Zevra Therapeutics Inc 2024年度报告

☐ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 For the fiscal year ended December 31, 2024 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period from ____ to _____ Commission File No. 001-36913 Zevra Therapeutics, Inc.(Exact Name of Registrant as Specified in Its Charter) Delaware20-5894398(State or Other Jurisdiction of Incorporationor Organization)(I.R.S. Employer Identification No.) 1180 Celebration Boulevard, Suite 103,Celebration, FL 34747(Address of Principal Executive Offices and Zip (Registrant’s Telephone Number, Including AreaCode) Code) Securities registered pursuant to Section 12(b) of the Act: Title of Each ClassTrading SymbolName of Each Exchange on WhichRegistered The Nasdaq Stock Market LLC(Nasdaq Global Select Market) Common Stock, $0.0001 par valueZVRA Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of theSecurities Act Yes☐No☐ Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) ofthe Act Yes☐No☐ Table of Contents Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that theregistrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90days. Yes☐No☐ Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File requiredto be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12months (or for such shorter period that the registrant was required to submit such files). Yes☐No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-acceleratedfiler, a smaller reporting company, or an emerging growth company. See the definitions of “large acceleratedfiler,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of theExchange Act.: Large accelerated filer☐Accelerated filer☐Non-accelerated filer☐Smaller reporting company☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extendedtransition period for complying with any new or revised financial accounting standards provided pursuantto Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’sassessment of the effectiveness of its internal control over financial reporting under Section 404(b) of theSarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued itsaudit report.☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financialstatements of the registrant included in the filing reflect the correction of an error to previously issued financialstatements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysisof incentive-based compensation received by any of the registrant's executive officers during the relevantrecovery period pursuant to § 240.10D-1(b).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the ExchangeAct). Yes☐No☐ on the Nasdaq Global Select Market on June 28, 2024. The calculation of the aggregate market value of votingand non-voting common equity excludes shares of common stock the registrant held by executive officers,directors and stockholders that the registrant concluded were affiliates of the registrant on that date. Exclusion ofsuch shares should not be construed to indicate that any such person possesses the power, direct or indirect, todirect or cause the direction of management or policies of the registrant or that such person is controlled by orunder common control with the registrant. As of March 7, 2025, the registrant had 54,115,869 shares of common stock outstanding. Documents Incorporated by Reference Portions of the registrant’s definitive proxy statement relating to its 2025 annual meeting of stockholders areincorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such proxystatement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of thefiscal year to which this report relates. Table of Contents ZEVRA THERAPEUTICS, INC.FORM 10-K PART I Item1.Business7Item1A.Risk Factors29Item1B.Unresolved Staff Comments76Item1C.CybersecurityItem2.Properties77Item3.Legal Proceedings77Item4.Mine Safety Disclosures77 PART II Item5.Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases